Literature DB >> 30598493

New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches.

Michal Bar-Natan1, Ronald Hoffman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30598493      PMCID： PMC6312005          DOI： 10.3324/haematol.2018.205989

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  21 in total

1.  Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis.

Authors:  Christoph Klatt; Irena Krüger; Saskia Zey; Kim-Jürgen Krott; Martina Spelleken; Nina Sarah Gowert; Alexander Oberhuber; Lena Pfaff; Wiebke Lückstädt; Kerstin Jurk; Martin Schaller; Hadi Al-Hasani; Jürgen Schrader; Steffen Massberg; Konstantin Stark; Hubert Schelzig; Malte Kelm; Margitta Elvers
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

2.  Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.

Authors:  Vittorio Rosti; Laura Villani; Roberta Riboni; Valentina Poletto; Elisa Bonetti; Lorenzo Tozzi; Gaetano Bergamaschi; Paolo Catarsi; Elena Dallera; Francesca Novara; Margherita Massa; Rita Campanelli; Gabriela Fois; Benedetta Peruzzi; Marco Lucioni; Paola Guglielmelli; Alessandro Pancrazzi; Giacomo Fiandrino; Orsetta Zuffardi; Umberto Magrini; Marco Paulli; Alessandro M Vannucchi; Giovanni Barosi
Journal:  Blood       Date:  2012-11-05       Impact factor: 22.113

Review 3.  Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.

Authors:  Nicholas Schwab; Tilman Schneider-Hohendorf; Heinz Wiendl
Journal:  Int Immunol       Date:  2014-10-17       Impact factor: 4.823

4.  Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo.

Authors:  Selcuk Sozer; Takefumi Ishii; Maria Isabel Fiel; Jiapeng Wang; Xiaoli Wang; Wei Zhang; Jim Godbold; Mingjiang Xu; Ronald Hoffman
Journal:  Blood Cells Mol Dis       Date:  2009-09-16       Impact factor: 3.039

Review 5.  Thrombocytosis and thrombosis.

Authors:  Alessandro M Vannucchi; Tiziano Barbui
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

6.  A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation.

Authors:  F Vincenti; R Mendez; M Pescovitz; P R Rajagopalan; A H Wilkinson; K Butt; D Laskow; D P Slakey; M I Lorber; J P Garg; M Garovoy
Journal:  Am J Transplant       Date:  2007-07       Impact factor: 8.086

7.  Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.

Authors:  Alberto Alvarez-Larrán; Manuel Pérez-Encinas; Francisca Ferrer-Marín; Juan Carlos Hernández-Boluda; María José Ramírez; Joaquín Martínez-López; Elena Magro; Yasmina Cruz; María Isabel Mata; Pilar Aragües; María Laura Fox; Beatriz Cuevas; Sara Montesdeoca; José Angel Hernández-Rivas; Valentín García-Gutiérrez; María Teresa Gómez-Casares; Juan Luis Steegmann; María Antonia Durán; Montse Gómez; Ana Kerguelen; Abelardo Bárez; Mari Carmen García; Concepción Boqué; José María Raya; Clara Martínez; Manuel Albors; Francesc García; Carmen Burgaleta; Carlos Besses
Journal:  Haematologica       Date:  2016-09-29       Impact factor: 9.941

8.  Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.

Authors:  T C Pearson; G Wetherley-Mein
Journal:  Lancet       Date:  1978-12-09       Impact factor: 79.321

9.  Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression.

Authors:  Alexandre Guy; Virginie Gourdou-Latyszenok; Nicolas Le Lay; Claire Peghaire; Badr Kilani; Juliana Vieira Dias; Cécile Duplaa; Marie-Ange Renault; Cécile Denis; Jean Luc Villeval; Yacine Boulaftali; Martine Jandrot-Perrus; Thierry Couffinhal; Chloe James
Journal:  Haematologica       Date:  2018-08-31       Impact factor: 9.941

10.  Hematopoietic Reprogramming In Vitro Informs In Vivo Identification of Hemogenic Precursors to Definitive Hematopoietic Stem Cells.

Authors:  Carlos-Filipe Pereira; Betty Chang; Andreia Gomes; Jeffrey Bernitz; Dmitri Papatsenko; Xiaohong Niu; Gemma Swiers; Emanuele Azzoni; Marella F T R de Bruijn; Christoph Schaniel; Ihor R Lemischka; Kateri A Moore
Journal:  Dev Cell       Date:  2016-03-07       Impact factor: 12.270
View more
  10 in total

1.  From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

Authors:  Brady L Stein; Karlyn Martin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.

Authors:  Radhika Gangaraju; Jihyun Song; Soo Jin Kim; Tsewang Tashi; Brandi N Reeves; Krishna M Sundar; Perumal Thiagarajan; Josef T Prchal
Journal:  Blood Adv       Date:  2020-03-24

3.  Familial thrombocythaemia - a distinct entity from essential thrombocythaemia.

Authors:  James Bussel; Nicole Kucine
Journal:  Br J Haematol       Date:  2021-08-02       Impact factor: 8.615

Review 4.  Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.

Authors:  Victor R Gordeuk; Nigel S Key; Josef T Prchal
Journal:  Haematologica       Date:  2019-03-14       Impact factor: 9.941

Review 5.  Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes.

Authors:  Danielle Cuthbert; Brady Lee Stein
Journal:  J Blood Med       Date:  2019-10-18

6.  Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia.

Authors:  Veronika Buxhofer-Ausch; Dominik Wolf; Siegfried Sormann; Ernst Forjan; Wolfgang Schimetta; Bettina Gisslinger; Sonja Heibl; Maria Theresa Krauth; Jürgen Thiele; Reinhard Ruckser; Heinz Gisslinger
Journal:  Eur J Haematol       Date:  2020-10-06       Impact factor: 2.997

7.  Causes of erythrocytosis and its impact as a risk factor for thrombosis according to etiology: experience in a referral center in Mexico City.

Authors:  Antonio Olivas-Martinez; Eduardo Corona-Rodarte; Adrián Nuñez-Zuno; Olga Barrales-Benítez; Daniel Montante-Montes de Oca; Jesús Delgado-de la Mora; Diana León-Aguilar; Hilda Elizeth Hernández-Juárez; Elena Tuna-Aguilar
Journal:  Blood Res       Date:  2021-09-30

8.  Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis.

Authors:  Mirko Farina; Simona Bernardi; Nicola Polverelli; Mariella D'Adda; Michele Malagola; Katia Bosio; Federica Re; Camillo Almici; Andrew Dunbar; Ross L Levine; Domenico Russo
Journal:  Cells       Date:  2021-10-15       Impact factor: 6.600

9.  Philadelphia-negative myeloproliferative neoplasms display alterations in monocyte subpopulations frequency and immunophenotype.

Authors:  Vitor Leonardo Bassan; Gabriel Dessotti Barretto; Felipe Campos de Almeida; Patrícia Vianna Bonini Palma; Larissa Sarri Binelli; João Paulo Lettieri da Silva; Caroline Fontanari; Ricardo Cardoso Castro; Lorena Lôbo de Figueiredo Pontes; Fabiani Gai Frantz; Fabíola Attié de Castro
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

Review 10.  The possible role of mutated endothelial cells in myeloproliferative neoplasms.

Authors:  Mirko Farina; Domenico Russo; Ronald Hoffman
Journal:  Haematologica       Date:  2021-11-01       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.